We waded through the sea of autism studies published in 2017 and spotted several themes.

A pruning protein reshapes neurons, culture should be a consideration in trials of autism treatments, and another U.S. state adds autism to the list of indications for medical cannabis.

The agency that oversees the drug approval process in Europe is moving to Amsterdam, gene editing gets its first human trial, and a tiny sensor detects even a few oxytocin molecules in blood.

A person’s ability to distinguish similar syllables by sight and sound correlates with how sensitive she is to sensory stimuli.

Mouse brains exposed to inflammation in the womb become more susceptible to a second challenge.

Two new gadgets join the gene-editing toolbox, many children with autism get smarter with age, and a survey points to a research reset for Autism Speaks.

Behavioral interventions and medications can help children with autism-related syndromes sleep better, but the treatments must be tailored to the cause of each child’s sleep disturbance.

Some infants who have an older sibling with autism show weak brain signals at 3 months of age.

A cannabis gel may ease features of fragile X syndrome, omega fatty acids show promise for autism in two trials, and oxytocin reinforces social behaviors through the brain’s reward pathway.

Immune cells in the brain called microglia play diverse roles in the mouse embryo but assume a common function by adolescence.